ProQR Therapeutics (PRQR) Stock Forecast & Price Target

$1.88

-0.01 (-0.53%)

(As of 07/26/2024 ET)

ProQR Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 4 Analyst Ratings

Based on 4 Wall Street analysts who have issued ratings for ProQR Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 4 analysts, 4 have given a buy rating for PRQR.

Consensus Price Target

$3.38
79.52% Upside

High Forecast	$5.00
Average Forecast	$3.38
Low Forecast	$2.00

According to the 4 analysts' twelve-month price targets for ProQR Therapeutics, the average price target is $3.38. The highest price target for PRQR is $5.00, while the lowest price target for PRQR is $2.00. The average price target represents a forecasted upside of 79.52% from the current price of $1.88.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Buy	Buy	Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$3.38	$3.38	$3.60	$4.35
Forecasted Upside	79.52% Upside	82.93% Upside	74.38% Upside	76.19% Upside

Get ProQR Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.

Ad American Hartford Gold Group

Prepare for a Recession Unlike Any Other

Dave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.

GET THE FREE GUIDE

PRQR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PRQR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ProQR Therapeutics Stock vs. The Competition

Type	ProQR Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.72	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	79.52% Upside	3,123.46% Upside	9.17% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/10/2024	Chardan Capital 2 of 5 stars	K. Nakae Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$2.50 ➝ $2.50	+21.36%
5/10/2024	HC Wainwright 3 of 5 stars		Reiterated Rating	Buy ➝ Buy	$5.00	+150.00%
4/18/2024	Citigroup 3 of 5 stars		Boost Target	Buy ➝ Buy	$1.80 ➝ $2.00	+1.52%
11/8/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$5.00 ➝ $4.00	+196.29%
5/17/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Kim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$5.00 ➝ $4.50	+152.81%
3/30/2023	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$1.50 ➝ $5.00	+98.41%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:59 AM ET.

PRQR Forecast - Frequently Asked Questions

What is ProQR Therapeutics' forecast for 2024?: According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for ProQR Therapeutics is $3.38, with a high forecast of $5.00 and a low forecast of $2.00.
Should I buy or sell ProQR Therapeutics stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRQR shares.
Does ProQR Therapeutics's stock price have much upside?: According to analysts, ProQR Therapeutics's stock has a predicted upside of 82.93% based on their 12-month stock forecasts.
What analysts cover ProQR Therapeutics?: ProQR Therapeutics has been rated by research analysts at Chardan Capital, and HC Wainwright in the past 90 days.
Do Wall Street analysts like ProQR Therapeutics more than its competitors?: Analysts like ProQR Therapeutics more than other "medical" companies. The consensus rating for ProQR Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how PRQR compares to other companies.